Pyripyropene A
Modify Date: 2024-01-09 21:54:44
Pyripyropene A structure
|
Common Name | Pyripyropene A | ||
|---|---|---|---|---|
| CAS Number | 147444-03-9 | Molecular Weight | 583.626 | |
| Density | 1.3±0.1 g/cm3 | Boiling Point | 690.8±55.0 °C at 760 mmHg | |
| Molecular Formula | C31H37NO10 | Melting Point | 153-154°C (lit.) | |
| MSDS | N/A | Flash Point | 371.6±31.5 °C | |
Use of Pyripyropene APyripyropene A is a potent and selective sterol O-acyltransferase 2 (SOAT2)/acyl-coenzyme A:cholesterol acyltransferase 2 (ACAT2) inhibitor, with an IC50 of 0.07 µM. Pyripyropene A attenuates hypercholesterolemia and atherosclerosis in vivo[1][2][3][4]. |
| Name | pyripyropene A |
|---|---|
| Synonym | More Synonyms |
| Description | Pyripyropene A is a potent and selective sterol O-acyltransferase 2 (SOAT2)/acyl-coenzyme A:cholesterol acyltransferase 2 (ACAT2) inhibitor, with an IC50 of 0.07 µM. Pyripyropene A attenuates hypercholesterolemia and atherosclerosis in vivo[1][2][3][4]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 0.07 µM (ACAT2)[1] |
| In Vitro | Pyripyropene A (0-100 µM; 72 hours) exhibits anti-proliferative activity against HUVECs, and with an IC50 value of 1.8 µM[1]. Pyripyropene A (10 µM ; 24 hours) inhibits VEGF (20 ng/ml)-induced migration and tubular formation of HUVECs in dose-dependent fashion[1]. Pyripyropene A do not show growth inhibitory effects against KB3-1, K562 and Neuro2A cells[1]. Cell Proliferation Assay[1] Cell Line: HUVECs Concentration: 0-100 µM Incubation Time: 72 hours Result: Exhibited anti-proliferative activity against HUVECs with an IC50 value of 1.8 µM. |
| In Vivo | Pyripyropene A (10-50 mg/kg per day; p.o; 12 weeks) reduces the levels of plasma cholesterol, very-low-density lipoprotein (VLDL), and low-density lipoprotein (LDL) and hepatic cholesterol content in apolipoprotein E-knockout mice. And Pyripyropene A-treated mice display reduction of atherogenic lesion areas in the aortae and heart[3]. Pyripyropene A inhibits the hepatic e acyl–coenzyme A:cholesterol acyltransferase 2 (ACAT2) activity in vivo[3]. Pyripyropene A displays a half-life (t1/2) of 0.693/λ, where λ represented the terminal slope of the log-linear portion of concentration time profile[4]. Animal Model: Male C57BL/6 mice[2] Dosage: 0 mg/kg, 1 mg/kg, 10 mg/kg, 50 mg/kg, 100 mg/kg Administration: Oral administration; daily; for 12 weeks Result: Reduced atherogenic lesion areas in the aortae and heart. Animal Model: 9-week old male ICR mice (pharmacokinetic analysis)[4] Dosage: 5 mg/kg ,10 mg/kg Administration: Oral administration Result: t1/2 = 0.693/λ |
| References |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 690.8±55.0 °C at 760 mmHg |
| Melting Point | 153-154°C (lit.) |
| Molecular Formula | C31H37NO10 |
| Molecular Weight | 583.626 |
| Flash Point | 371.6±31.5 °C |
| Exact Mass | 583.241760 |
| PSA | 151.46000 |
| LogP | 2.68 |
| Vapour Pressure | 0.0±2.3 mmHg at 25°C |
| Index of Refraction | 1.587 |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| Homopurine |
| 1,3,5,7-Tetraazanaphthalene |
| (3S,4R,4aR,6S,6aS,12R,12aS,12bS)-4-(Acetoxymethyl)-12-hydroxy-4,6a,12b-trimethyl-11-oxo-9-(pyridin-3-yl)-1,3,4,4a,5,6,6a,12,12a,12b-decahydro-2H,11H-benzo[f]pyrano[4,3-b]chromene-3,6-diyl diacetate |
| (3S,4R,4aR,6S,6aS,12R,12aS,12bS)-4-(Acetoxymethyl)-12-hydroxy-4,6a,12b-trimethyl-11-oxo-9-(3-pyridinyl)-1,3,4,4a,5,6,6a,12,12a,12b-decahydro-2H,11H-benzo[f]pyrano[4,3-b]chromene-3,6-diyl diacetate |
| 2H,11H-Naphtho[2,1-b]pyrano[3,4-e]pyran-11-one, 3,6-bis(acetyloxy)-4-[(acetyloxy)methyl]-1,3,4,4a,5,6,6a,12,12a,12b-decahydro-12-hydroxy-4,6a,12b-trimethyl-9-(3-pyridinyl)-, (3S,4R,4aR,6S,6aS,12R,12aS,12bS)- |
| pyripropen A |
| Pyrimidopyrimidin |